Incyte: Canada Approves Minjuvi in Combination With Lenalidomide for Lymphoma
24 August 2021 - 03:16PM
Dow Jones News
By Michael Dabaie
Incyte Corp. said Health Canada approved Minjuvi in combination
with lenalidomide for the treatment of adult patients with relapsed
or refractory diffuse large B-cell lymphoma.
The conditional approval is based on data from the L-MIND study
and is supported by the RE-MIND study, an observational
retrospective study in relapsed or refractory DLBCL. Removal of the
conditions is contingent upon verification and description of
clinical benefit in a confirmatory trial.
DLBCL is the most common type of non-Hodgkin lymphoma in adults
worldwide, Incyte said, and is characterized by rapidly growing
masses of malignant B-cells in the lymph nodes, spleen, liver, bone
marrow or other organs.
Incyte and MorphoSys AG share global development rights to
tafasitamab; Incyte has exclusive commercialization rights to
tafasitamab outside the U.S. Tafasitamab is co-marketed by Incyte
and MorphoSys under the brand name Monjuvi in the U.S. and is
marketed by Incyte under the brand name Minjuvi in Canada.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 24, 2021 09:14 ET (13:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Morphosys (TG:MOR)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Morphosys (TG:MOR)
Historical Stock Chart
Von Mär 2023 bis Mär 2024